Actively Recruiting
Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer
Led by Pingping Song · Updated on 2025-06-12
26
Participants Needed
1
Research Sites
313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single-arm, exploratory trial to evaluate the efficacy and safety of neoadjuvant WX-0593 in patients with resectable ALK-positive or ROS1- positive non-small cell lung cancer(NSCLC).
CONDITIONS
Official Title
Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed non-small cell lung cancer (NSCLC)
- ALK-positive or ROS1-positive NSCLC in Stage IB-IIIA (8th AJCC TNM edition), as assessed by investigator
- Complete surgical resection of the primary NSCLC must be achievable, as assessed by a multidisciplinary team including a thoracic oncologic surgeon
- ECOG Performance Status of 0-1
- At least one measurable lesion according to RECIST 1.1
- Adequate organ and marrow function
You will not qualify if you...
- Prior systemic anti-cancer therapy for NSCLC including chemotherapy, biologic therapy, immunotherapy, or investigational drugs
- Prior treatment with ALK tyrosine kinase inhibitors or ROS1 tyrosine kinase inhibitors
- Prior local radiotherapy
- Mixed small cell and NSCLC histology
- Patients eligible only for segmentectomies or wedge resections
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shandong Cancer Hospital and Institute
Jinan, Shandong, China, 250117
Actively Recruiting
Research Team
P
Pingping Song
CONTACT
G
Guodong Zhang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here